Cancer最新文献

{"title":"Correction to “Clinical and immunologic characteristics of nonhematologic autoimmune disorders in chronic lymphocytic leukemia”","authors":"","doi":"10.1002/cncr.70325","DOIUrl":"10.1002/cncr.70325","url":null,"abstract":"<p>Arguello-Tomas M, Lynton-Pons E, Albiol N, et al. Clinical and immunologic characteristics of nonhematologic autoimmune disorders in chronic lymphocytic leukemia. <i>Cancer</i>. 2025;e70216. doi:10.1002/cncr.70216</p><p>In the affiliations of the authors, affiliation number 3 was incorrect and should be: “Departament de Medicina, Facultat de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain”</p><p>In Table 1, FISH cytogenetics; Unmutated IGHV genes, no. (%); Mutated <i>TP53</i>, no. (%); Clinical progression requiring treatment for CLL, no. (%); and Time to first treatment: Median [range], years are independent variables and should not be grouped under Rai stage at diagnosis, no. (%). The FISH cytogenetics information was wrongly exposed. The updated version of Table 1 is as follows:</p><p>On page 5, the sentence should be “Among patients who had nonhematologic AIDs, we observed that patients who had psoriasis had the lowest risk of requiring antileukemic treatment, with a significantly longer TTFT compared with those who had other AIDs (median TTFT not reached, and TTFT at 15 years, 65.7% vs. 48.1%, respectively; <i>p</i> = .04; Figure 1 and Figure S1A).”</p><p>On page 9, the sentence should be “To our knowledge, this is the first comprehensive study reporting the prevalence, clinical and biologic characteristics, and prognosis of patients with CLL who have nonhematologic AIDs.”</p><p>We apologize for these errors.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 5","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70325","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147281516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early-life body size and risk of developing biliary tract cancers","authors":"Prema S. Bhattacharjee PhD, MPH,&nbsp;Jennifer L. Baker PhD,&nbsp;Ruth M. Pfeiffer PhD,&nbsp;Sarah S. Jackson PhD, MPH,&nbsp;Julie Aarestrup PhD,&nbsp;Jill Koshiol PhD","doi":"10.1002/cncr.70303","DOIUrl":"10.1002/cncr.70303","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Childhood body mass index (BMI) trajectories, BMI, height, and birth weight were investigated in relation to biliary tract cancer (BTC) risk in this population-based cohort study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The study included 172,113 males and 168,503 females born between 1930 and 1996 from the Copenhagen School Health Records Register. Heights and weights measured at ages 6–15 years identified five sex-specific BMI trajectories. BMI and height were analyzed as <i>z</i> scores; overweight was defined via US Centers for Disease Control and Prevention criteria. Sex-specific hazard ratios (HRs) were estimated via birth cohort–stratified Cox regressions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>During a median follow-up of 34.5 years, 635 individuals developed BTCs. Overweight (HR, 1.58; 95% confidence interval [CI], 1.06–2.34) and obesity trajectories in males (HR, 3.22; 95% CI, 1.61–6.44) and the obesity trajectory in females (HR, 2.88; 95% CI, 1.62–5.15) were associated with increased BTC risk compared with the average BMI trajectory. Childhood overweight at age 7 years was associated with increased intrahepatic bile duct cancer risk in males (HR, 2.66; 95% CI, 1.48–4.75) and extrahepatic bile duct cancer risk in females (HR, 3.83; 95% CI, 1.94–7.56). Taller childhood height was linked to a higher BTC risk in males only; birth weight showed no associations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Childhood overweight and obesity increase BTC risk in adulthood.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 5","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12930340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147281529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initial chemotherapy dose reductions and subsequent treatment delivery in stage I–IIIA breast cancer","authors":"Maria J. Monroy-Iglesias MBBS, PhD,&nbsp;Kelli O’Connell MSPH,&nbsp;Jenna Bhimani MBBS, MPH,&nbsp;Victoria S. Blinder MD, MS,&nbsp;Rachael P. Burganowski-Doud MS,&nbsp;Isaac J. Ergas PhD, MPH, MFA,&nbsp;Grace B. Gallagher MPH,&nbsp;Jennifer J. Griggs MD, MPH,&nbsp;Narre Heon MPA,&nbsp;Tatjana Kolevska MD,&nbsp;Yuriy Kotsurovskyy MD,&nbsp;Candyce H. Kroenke ScD,&nbsp;Cecile A. Laurent MS,&nbsp;Raymond Liu MD,&nbsp;Kanichi G. Nakata PhD,&nbsp;Sonia Persaud MPH,&nbsp;Janise M. Roh MSW, MPH,&nbsp;Yashasvini Sampathkumar MD,&nbsp;Sara Tabatabai MPP,&nbsp;Emily Valice MPH,&nbsp;Peng Wang PhD,&nbsp;Erin J. Aiello Bowles MPH,&nbsp;Elisa V. Bandera MD, PhD,&nbsp;Lawrence H. Kushi ScD,&nbsp;Elizabeth D. Kantor PhD, MPH","doi":"10.1002/cncr.70294","DOIUrl":"10.1002/cncr.70294","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>For most cytotoxic drugs, guidelines recommend body-surface-area–based dosing, yet some patients start with reduced doses, potentially reflecting tolerability concerns. The relationship between first-cycle dose reductions and subsequent delivery is unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The authors analyzed data from women with stage I–IIIA breast cancer treated with adjuvant chemotherapy. Sankey diagrams illustrated trajectories from first-cycle dose proportion (FCDP) to average relative dose intensity (ARDI, ratio of received to expected dose intensity across the regimen), and cumulative dose proportion (CDP, ratio of total received to expected dose). Poisson regression estimated adjusted prevalence ratios for reduced FCDP (&lt;95% vs. ≥95%) and three outcomes: ARDI reduction beyond initial FCDP, receiving fewer cycles, and CDP reduction beyond initial FCDP. Analyses assessed effect modification by age, body mass index (BMI), and comorbidities. Dosing was analyzed for cytotoxic and HER2-targeted therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 8772 (90.8%) patients started with FCDP ≥95%; most maintained ARDI ≥95% (65.1%) and CDP ≥95% (79.9%). In multi-variable models, FCDP &lt;95% was not significantly associated with further ARDI or CDP reductions or receipt of fewer cycles. BMI modified these associations (<i>p</i>-interaction = .004 for fewer cycles; <i>p</i>-interaction = .03 for CDP), with positive associations among overweight but not obese or normal-weight patients. FCDP &lt;95% was linked to a lower likelihood of further ARDI reductions for both therapy types and lower likelihood of cumulative dose reduction in HER2-targeted therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Early dosing decisions shaped subsequent chemotherapy delivery. Most patients who began at full dose maintained consistent dosing, whereas early reductions did not stave off subsequent changes, underscoring the need to balance safety with adequate dose intensity.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 5","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147275285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of mental health disorders and all-cause mortality for patients with cancer: Large-scale analysis of University of California Health System Data","authors":"Amir Ashraf Ganjouei MD, MPH,&nbsp;Travis Zack MD, PhD,&nbsp;Isabel Friesner BA,&nbsp;William C. Chen MD,&nbsp;Lauren Boreta MD,&nbsp;Steve E. Braunstein MD, PhD,&nbsp;Michael W. Rabow MD,&nbsp;Maria E. Garcia MD, MPH,&nbsp;Julian C. Hong MD, MS","doi":"10.1002/cncr.70254","DOIUrl":"10.1002/cncr.70254","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Cancer diagnoses are associated with considerable psychological distress and increased incidence of new mental health disorders (MHDs). Our aim was to identify patterns and differences in the emergence of new MHDs within the first year following a cancer diagnosis, using data from a diverse, multi-institutional cancer cohort including more than half a million patients within a statewide academic health system.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The University of California Data Discovery Platform was used, which aggregates data of all patients at University of California–affiliated hospitals. We identified a cohort consisting of all adult patients with a cancer diagnosis and no documented MHDs before cancer diagnosis between 2013 and 2023. Multivariable adjusted time-partitioned hazard ratios for overall all-cause mortality were constructed using epochs of 12 through 35, 36 through 59, and 60 through 120 months.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 371,897 patients (mean age, 62.1 years) did not have a diagnosis. Following an incident cancer diagnosis, 39,687 patients (10.6%) developed a new MHD within a year. Of these, 13,904 (35.0%) were newly prescribed one or more oral psychotropic medications. After adjusting for covariates, early MHD was found to be linked to increased all-cause mortality in the initial 12 through 35 months (hazard ratio, 1.51; 95% CI, 1.47–1.56), which diminished over time, observed as 1.17 (95% CI, 1.11–1.24) for 36 through 59 months and 0.95 (95% CI, 0.89–1.01) for 60 through 120 months.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Patients with cancer who experience a mental health condition are at an increased risk of all-cause mortality. This reinforces and emphasizes existing recommendations for prompt screening and management of distress and mental health following a cancer diagnosis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 5","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12926721/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147269222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of a sexual quality of life intervention for couples facing metastatic breast cancer: Results of a randomized controlled trial","authors":"Jennifer B. Reese PhD,&nbsp;Lauren A. Zimmaro PhD,&nbsp;Kristen A. Sorice BA,&nbsp;Li Zhang PhD,&nbsp;Jessica R. Gorman PhD, MPH,&nbsp;Mary B. Daly MD, PhD,&nbsp;Alexandra K. Zaleta PhD,&nbsp;Laura S. Porter PhD","doi":"10.1002/cncr.70334","DOIUrl":"10.1002/cncr.70334","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Patients with metastatic breast cancer (MBC) often report severe, long-standing concerns with their sexual quality of life (QOL), yet interventions for this population are scarce. This study evaluated the efficacy of a couple-based sexual QOL intervention adapted for MBC couples in a randomized controlled trial.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Fifty-five female MBC patients reporting sexual concerns and their intimate partners (<i>N</i> = 110 participants) were randomized to Adapted Intimacy Enhancement (AIE), a four-session videoconference intervention providing education and skills training for coping with sexual/intimacy concerns, or Enhanced Care-As-Usual (ECAU; informational booklet). Outcomes (measured at baseline, post-intervention, and 6-month follow-up) included patients’ sexual outcomes (sexual function/distress/self-efficacy; primary), patients’ psychosocial outcomes (sexual communication, relationship intimacy, and psychological distress; secondary), and similar partner outcomes (secondary). Mixed linear regression models assessed intervention effects on outcomes at follow-ups; psychosocial outcomes were analyzed using dyadic analyses. Effect sizes (Cohen’s <i>d</i>) were calculated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Compared to ECAU, patients in AIE reported greater improvements in overall sexual function (<i>p</i> = .018), desire (<i>p</i> = .007), and sexual distress (<i>p</i> = .046) at 6 months, and in sexual satisfaction at both post-intervention (<i>p</i> = .02) and 6 months (<i>p</i> &lt; .001). Partners in AIE reported greater improvements in sexual distress (<i>p</i> = .006), sexual self-efficacy (<i>p</i> = .008), sexual communication (<i>p</i> = .004), and relationship intimacy (<i>p</i> = .01) at 6 months. Effects were largest for patient sexual satisfaction and partner sexual distress at 6 months.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Compared to a detailed informational booklet on sex/intimacy, the couple-based AIE intervention yielded long-term benefits for MBC patients’ sexual outcomes and partners’ sexual distress and psychosocial outcomes. Future research should identify intervention mediators and optimal dissemination methods.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 5","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146775802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the feasibility and efficacy of exercise interventions for older survivors of cancer","authors":"Jingran Ji MD,&nbsp;Arman Niknafs MD,&nbsp;Lee W. Jones PhD","doi":"10.1002/cncr.70278","DOIUrl":"10.1002/cncr.70278","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 5","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146256758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shifting toward chronicity: The new reality of chronic treatments and health conditions among adolescent and young adult patients with cancer","authors":"Alice Indini MD,&nbsp;Angela Toss MD,&nbsp;Elisabetta Razzaboni PhD,&nbsp;Elena Pagani Bagliacca MSc,&nbsp;Giulia Zucchetti PhD,&nbsp;Paola Quarello MD,&nbsp;Maurizio Mascarin MD,&nbsp;Mara Cologgi,&nbsp;Michele Del Vecchio MD,&nbsp;Fedro Peccatori MD,&nbsp;Andrea Ferrari MD","doi":"10.1002/cncr.70321","DOIUrl":"10.1002/cncr.70321","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 5","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146256816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consensus recommendations in the management of jaw (gnathic) osteosarcoma","authors":"Matthew S. Dietz DO, MSEd,&nbsp;Lara E. Davis MD,&nbsp;Pinki K. Prasad MD, MPH,&nbsp;Shauna R. Campbell DO,&nbsp;John D. Reith MD,&nbsp;Mallery R. Olsen MD,&nbsp;Scott E. Kilpatrick MD,&nbsp;Jamie A. Ku MD,&nbsp;Natalie L. Silver MD, MS,&nbsp;Earl P. Park MD, DMD,&nbsp;Elisa Tirtei MD, PhD,&nbsp;Cristina Meazza MD,&nbsp;Erin S. Murphy MD,&nbsp;Nicole C. Mallory MD,&nbsp;Emanuela Palmerini MD, PhD,&nbsp;Leo Kager MD,&nbsp;Marinka L. F. Hol MD, PhD,&nbsp;Roel of van Ewijk MD,&nbsp;Joseph Lopez MD, MBA,&nbsp;Leighton A. Elliott MD,&nbsp;Dale R. Shepard MD, PhD,&nbsp;Ajay Gupta MD, MS,&nbsp;Matteo M. Trucco MD","doi":"10.1002/cncr.70273","DOIUrl":"https://doi.org/10.1002/cncr.70273","url":null,"abstract":"<p>Gnathic osteosarcoma (OS), which includes mandibular and maxillary jaw OSs, account for 6%–9% of OS. Single-institutional and multi-institutional retrospective studies, as well as population-level databases, suggest that clinical differences exist among gnathic OS and OS of other sides, including other craniofacial OS. To date, no specific prospective studies of gnathic OS have been reported, and aspects of clinical management are controversial. Some elements of care are aligned with extragnathic OS, e.g., margin negative (R0) surgery, whereas others, such as chemotherapy and radiation, are not clearly defined. The authors reviewed the available literature for the diagnosis, treatment, and supportive/survivorship care patients with gnathic OS and offer consensus statements for the comprehensive management of this rare disease.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 5","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70273","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146224285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sacituzumab tirumotecan improved survival for patients with EGFR TKI–resistant, EGFR-mutant advanced NSCLC","authors":"Leah Lawrence","doi":"10.1002/cncr.70250","DOIUrl":"10.1002/cncr.70250","url":null,"abstract":"&lt;p&gt;The TROP2-targeting antibody–drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival (PFS) and overall survival (OS) in comparison with pemetrexed plus platinum-based therapy in patients with EGFR-mutated non–small cell lung cancer (NSCLC) that had progressed after an EGFR tyrosine kinase inhibitor (TKI) according to the results of the OptiTROP-Lung04 trial.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;These findings, which were presented at the 2025 European Society for Medical Oncology Congress by Li Zhang, MD, an oncologist at the Guangdong Provincial Clinical Research Center for Cancer in Guangzhou, China, and were published simultaneously in &lt;i&gt;The New England Journal of Medicine&lt;/i&gt;, confirmed the findings from an earlier phase 2 trial of sac-TMT, which showed significant improvements in PFS and OS in comparison with docetaxel.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;The phase 3 trial enrolled 376 patients with EGFR-mutated locally advanced or metastatic nonsquamous NSCLC that had progressed after a prior EGFR TKI (94.7% of the patients had received a third-generation EGFR TKI). Patients were randomly assigned to sac-TMT or pemetrexed plus platinum-based chemotherapy. The trial enrolled only Asian patients.&lt;/p&gt;&lt;p&gt;The final PFS analysis showed a 4-month improvement in median PFS with sac-TMT in comparison with chemotherapy (8.3 vs. 4.3 months; hazard ratio [HR], 0.49; 95% CI, 0.39–0.62).&lt;/p&gt;&lt;p&gt;A preplanned interim OS analysis that was conducted at a median follow-up of 18.9 months showed a 40% reduction in the risk for death with sac-TMT versus chemotherapy (HR, 0.60; 95% CI, 0.44–0.82; two-sided &lt;i&gt;p&lt;/i&gt; = .001). The median OS was not reached for patients on sac-TMT but was 17.4 months for patients on chemotherapy. The OS rate at 18 months was 65.8% for patients on sac-TMT and 48.0% for patients on chemotherapy.&lt;/p&gt;&lt;p&gt;The majority of the patients who discontinued the trial went on to have subsequent anticancer treatment. Approximately half of the patients in the sac-TMT arm (41.9%) and the chemotherapy arm (53.6%) had subsequent chemotherapy. Subsequent ADCs were given to 1.4% of the patients assigned to sac-TMT and to 19.6% of the patients assigned to chemotherapy.&lt;/p&gt;&lt;p&gt;The rates of grade 3 or higher treatment-related adverse events were similar for sac-TMT (58.0%) and chemotherapy (53.8%), but treatment-related serious events were less common with sac-TMT (9.0% vs. 17.6%). The researchers noted that patients assigned to sac-TMT had a higher rate of stomatitis than patients assigned to chemotherapy (64.4% vs. 4.9%), with 10.1% of the patients assigned to sac-TMT requiring a dose reduction because of stomatitis.&lt;/p&gt;&lt;p&gt;Time to deterioration of global quality of life was longer with sac-TMT than chemotherapy. Additionally, Dr Zhang and colleagues looked at patient-reported outcomes. Patient-reported outcome curves had a “slight overlap” up to 3 months from initiation but showed a consistent separation after that.&lt;","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 4","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70250","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146224628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TROP2-targeted ADCs demonstrate survival benefit for patients with advanced triple-negative breast cancer","authors":"Leah Lawrence","doi":"10.1002/cncr.70249","DOIUrl":"10.1002/cncr.70249","url":null,"abstract":"&lt;p&gt;Data from two phase 3 trials presented at the 2025 European Society for Medical Oncology Congress demonstrated that patients with triple-negative breast cancer (TNBC) benefited from the first-line use of TROP2-targeted antibody–drug conjugates (ADCs). The ASCENT-03 trial, which tested sacituzumab govitecan, and the TROPION-Breast02 trial, which tested datopotamab deruxtecan (Dato-DXd), compared the ADCs with chemotherapy in patients for whom immunotherapy was not a treatment option. Both demonstrated significant survival benefits.&lt;span&gt;&lt;sup&gt;1, 2&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;“About 60% of patients with TNBC, which affects about 40,000 people annually in the United States, are not candidates for immunotherapy,” says Ruth O’Regan, MD, chair of the Department of Medicine at the University of Rochester in New York. “Treatment options are limited to chemotherapy in these patients, and in most cases, patients experience disease progression within six months of starting this treatment.”&lt;/p&gt;&lt;p&gt;The phase 3 ASCENT-03 trial enrolled 558 patients with previously untreated advanced TNBC who were not candidates for PD-1 or PD-L1 inhibitors. Patients were randomly assigned to sacituzumab govitecan or chemotherapy.&lt;/p&gt;&lt;p&gt;Almost a 3-month improvement was seen in median progression-free survival (PFS) for patients assigned to sacituzumab govitecan in comparison to those assigned to chemotherapy (9.7 vs. 6.9 months; hazard ratio [HR], 0.62; 95% CI, 0.50–0.77; &lt;i&gt;p&lt;/i&gt; &lt; .001). Objective response rates were similar in the two treatment arms, with a little less than half of patients responding. However, the median duration of response was approximately 4 months longer for patients assigned to sacituzumab govitecan (12.2 months) in comparison to those assigned to chemotherapy (7.2 months), which Dr O’Regan calls a “meaningful prolongation of disease control.”&lt;/p&gt;&lt;p&gt;In addition, only 4% of patients assigned to the ADC discontinued treatment because of treatment-emergent adverse events, whereas 12% of patients assigned to chemotherapy did.&lt;/p&gt;&lt;p&gt;TROPION-Breast02 enrolled 644 patients with previously untreated advanced TNBC for whom immunotherapy was not an option. Patients were randomly assigned to Dato-DXd or the investigator’s choice of chemotherapy.&lt;/p&gt;&lt;p&gt;Treatment with Dato-DXd resulted in a significant improvement in median overall survival (23.7 vs. 18.7 months; HR, 0.79; 95% CI, 0.64–0.98; &lt;i&gt;p&lt;/i&gt; = .0291) and median PFS (10.8 vs. 5.6 months; HR, 0.57; 95% CI, 0.47–0.69; &lt;i&gt;p&lt;/i&gt; &lt; .0001) in comparison with chemotherapy. Patients assigned to Dato-DXd also had improved overall response rates (62.5% vs. 29.3%) and a longer median duration of response (12.3 vs. 7.1 months) in comparison with those assigned to chemotherapy.&lt;/p&gt;&lt;p&gt;“These results are meaningful,” Dr O’Regan says, “with a five-month improvement in both PFS and overall survival.”&lt;/p&gt;&lt;p&gt;Again, rates of discontinuations were lower with the ADC than with chemotherapy (4.4% vs. 7.4%).&lt;/p&gt;&lt;p&gt;Javier C. Cortés, ","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 4","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70249","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146224801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}